ALSO NOTED: Enzon sells drug interest; Generex gains new patents; Access plans trials;and much more...

> Enzon has sold a 25 percent interest in the hepatitis C drug Peg-Interferon for $92.5 million. Release

> Generex Biotechnology has been awarded new patents in Europe and Mexico. Release

> Access Pharmaceuticals says that it intends to start new human trials of ProLindac, its novel DACH platinum polymer prodrug. Release

> Score one for Novartis. Its once-yearly treatment for post-menopausal osteoporosis, Reclast, now has the FDA's blessing. FiercePharma

> Abbott Laboratories is opting to reshuffle executive responsibilities rather than filling its No. 2 management slot. FiercePharma

> Use of prescription pain pills has skyrocketed over the past several years, according to a government study. Sales of the five biggest painkillers jumped 90 percent between 1997 and 2005. FiercePharma

And Finally… Researchers say that some parents are too eager to share the results of genetic tests with children who are too young to understand what they are being told. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.